drugset / Trial / NCT04825275

Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial

NCT04825275

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This research is being done to find out if the study drug (posaconazole) can enter brain tumors at a high enough amount to stop the tumor cells from dividing. Posaconazole is a drug which doctors already use for fungal infections and is thought to be able to effect tumor cells. As treatments for this type of brain tumor are limited, it is hoped that the results of this study will help to determine if the study drug should be studied further as a possible treatment.

Timeline

Start
2022-05-13
Primary completion
2024-11-06
Completion
2024-11-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Posaconazole Small molecule 300 mg Oral